Bruker (NASDAQ:BRKR) Issues Earnings Results

Bruker (NASDAQ:BRKR) issued its quarterly earnings data on Wednesday. The medical research company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.14, FiscalAI reports. The business had revenue of $874.00 million for the quarter, compared to analysts’ expectations of $865.16 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 EPS.

Here are the key takeaways from Bruker’s conference call:

• Margins and adjusted EPS improved sharply: Q3 non-GAAP operating margin rose 400 basis points to 16.3%, and diluted non-GAAP EPS increased 24% to $0.56, helped by cost savings and favorable product mix.
• Bookings point to improving demand: BSI book-to-bill remained above one for a fifth consecutive quarter, with year-to-date bookings and backlog up mid-single digits. Management cited strong China demand, a return to U.S. academic and government bookings growth, and more than 30% year-to-date growth in semiconductor metrology orders.
• Bruker reaffirmed its 2026 organic revenue growth outlook of 1%–2% and non-GAAP EPS range of $2.10–$2.15; it expects lower-mid-single-digit organic revenue growth in Q4. Management said 2027 should bring faster organic growth, further margin expansion, and double-digit EPS growth, while noting detailed guidance will come in February.
• Reported growth remained modest: Q3 organic revenue increased just 0.7%, while BSI organic revenue declined 0.4%, partly due to previously disclosed semiconductor instrument pushouts. GAAP results included a roughly $175 million non-cash goodwill impairment tied to Bruker Spatial Biology and a diluted loss per share of $0.81.

Bruker Trading Up 11.0%

BRKR traded up $6.20 during trading on Wednesday, reaching $62.70. The company had a trading volume of 4,671,929 shares, compared to its average volume of 2,365,464. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The business has a 50 day simple moving average of $58.81 and a 200-day simple moving average of $50.41. The stock has a market cap of $9.55 billion, a P/E ratio of -89.81, a PEG ratio of 1.70 and a beta of 1.26. Bruker has a 52 week low of $32.37 and a 52 week high of $68.98.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were given a $0.05 dividend. The ex-dividend date was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Insiders Place Their Bets

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 27.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on BRKR. Stifel Nicolaus set a $50.00 price target on shares of Bruker in a research report on Wednesday, August 5th. JPMorgan Chase & Co. lowered shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research report on Wednesday, October 14th. The Goldman Sachs Group raised shares of Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Zacks Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, Barclays upped their target price on shares of Bruker from $58.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and a consensus price target of $59.43.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported third-quarter earnings of $0.56 per share, above the $0.42 consensus estimate and up from $0.45 a year earlier. Revenue of $874 million also exceeded expectations of $865.16 million, with sales rising 1.6% year over year. The earnings and revenue beats are the clearest near-term catalysts for the shares. Read article
• Positive Sentiment: Bruker said U.S. academic-market demand returned in Q3 and is targeting double-digit EPS growth in fiscal 2027, suggesting a potential improvement in a market that had been an overhang. Read article
• Neutral Sentiment: For 2026, Bruker forecast revenue of $3.52 billion to $3.56 billion, putting the midpoint slightly below FactSet’s $3.56 billion estimate. Its non-GAAP EPS outlook of $2.10 to $2.15 brackets the $2.12 consensus, broadly aligning with expectations. Read article
• Negative Sentiment: A report highlighted a steep goodwill charge despite improved margins, raising a potential concern about reported results and earnings quality. Read article

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.